← Back to Search

Enuresis Alarm

Novel Enuresis Alarm vs Standard Alarm for Bedwetting

N/A
Recruiting
Led By Israel Franco, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female, aged 6 to 21 years
Be younger than 65 years old
Must not have
No patient with known Chronic renal disease with moderate to severe renal impairment (defined as a creatinine clearance below 50mL/min)
Presence of Autistic Spectrum disorder, ADHD, genetic syndrome associated with developmental or learning disabilities
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 month period
Awards & highlights
No Placebo-Only Group

Summary

This trial compares two bedwetting devices, GoGoband® and another device, in children who wet the bed but do not have ADHD. Both devices work by waking the child when they start to wet the bed, helping them learn to stay dry. The body-worn alarm has been shown to be as effective as other methods and superior in terms of rapidity of response and consumer appeal.

Who is the study for?
This trial is for boys and girls aged 6 to 21 who are generally healthy but struggle with bedwetting (MNE). They must be able to follow the study's procedures, have not used any bedwetting treatments in the last six months, and cannot be on certain medications like ADHD drugs or antidepressants. Those with conditions such as autism, developmental disabilities, diabetes, severe kidney issues or a history of low sodium levels can't join.
What is being tested?
The study is testing how effective a new device called GoGoband® is compared to a standard Pflaundler alarm in helping patients achieve dry nights. Participants will use one of these two alarms at random to see which one works better for stopping bedwetting.
What are the potential side effects?
Since this trial involves non-invasive devices aimed at reducing bedwetting incidents rather than medication, side effects may include discomfort from wearing the device overnight or potential sleep disturbances due to alarm activation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 6 and 21 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidneys work well (creatinine clearance above 50mL/min).
Select...
I have been diagnosed with autism, ADHD, or a genetic condition affecting my learning.
Select...
I haven't received any treatment for bedwetting in the last 6 months.
Select...
I am currently taking medication for ADHD, depression, or psychosis.
Select...
I have diabetes.
Select...
I do not have, nor have I had, low sodium levels in my blood.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 month period
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 month period for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of wet nights

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: gogoband alarmExperimental Treatment1 Intervention
patients will be assigned to the novel bedwetting alarm
Group II: standard nocturnal enuresis alarm (SNEA) groupActive Control1 Intervention
this is the standard bedwetting alarm that is presently available through out the world

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Behavioral conditioning devices, such as the GoGoband® nocturnal enuresis device, use vibration or sound to wake the patient when wetness is detected. This method conditions the brain to recognize the sensation of a full bladder and wake up before urination occurs, thereby helping to develop bladder control and reduce bedwetting episodes. This approach is crucial for bedwetting patients as it promotes long-term improvement in bladder awareness and control. Other common treatments include medications like desmopressin, which reduces urine production at night, and lifestyle changes such as limiting fluid intake before bedtime.

Find a Location

Who is running the clinical trial?

Food and Drug Administration (FDA)FED
181 Previous Clinical Trials
1,548,678 Total Patients Enrolled
Southwest pediatric Device ConsortiumUNKNOWN
Yale UniversityLead Sponsor
1,920 Previous Clinical Trials
3,031,383 Total Patients Enrolled

Media Library

GoGoband® Nocturnal Enuresis Device (Enuresis Alarm) Clinical Trial Eligibility Overview. Trial Name: NCT05214131 — N/A
Bedwetting Research Study Groups: gogoband alarm, standard nocturnal enuresis alarm (SNEA) group
Bedwetting Clinical Trial 2023: GoGoband® Nocturnal Enuresis Device Highlights & Side Effects. Trial Name: NCT05214131 — N/A
GoGoband® Nocturnal Enuresis Device (Enuresis Alarm) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05214131 — N/A
Bedwetting Patient Testimony for trial: Trial Name: NCT05214131 — N/A
~3 spots leftby Jan 2025